Concurrent use of statins and amíodarone

Consultant Pharmacist

Volumn 24, Issue 5, 2009, Pages 372-379

  Borders Hemphill, Vicky ^a,b  

^a Office of Surveillance and Epidemiology   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

3 hydro y 3 methyl glutaryl coenzyme A; Amiodarone; Concurrent use; HMG CoA; Myopathy; Reductase inhibitors; Rhabdomyolysis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMIODARONE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATAZANAVIR; ATORVASTATIN; CEFTRIAXONE; CLARITHROMYCIN; DIGITOXIN; DOSULEPIN; EZETIMIBE PLUS SIMVASTATIN; FERROUS SULFATE; FLUINDOSTATIN; FLUNISOLIDE; GENERIC DRUG; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LANSOPRAZOLE; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; MYOGLOBIN; PHENPROCOUMON; PRAVASTATIN; SALBUTAMOL; SALMETEROL; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; ANTIARRHYTHMIC AGENT;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; HUMAN; MYALGIA; MYOPATHY; PRESCRIPTION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SYMPTOM; AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; DRUG MONITORING; FACTUAL DATABASE; FEMALE; LONGITUDINAL STUDY; MALE; MIDDLE AGED;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS;

EID: 66749174587     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.372     Document Type: Article

References (24)

1. SDI, LLC: Vector One: National (VONA). Data extracted November 8, 2007.
2. SDI, LLC: Vector One: National (VONA). Data extracted July 2, 2008.
3. Wolters Kluwer Health, Inc. Facts & Comparisons 4.0. Amiodarone hydrochloride oral monograph. Available at http://online.factsandcomparisons. com. Accessed November 20, 2007.
4. Vassallo P,Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312-22.
5. Food and Drug Administration, supplemental NDA #18-972/S-036 for Cordarone labeling revision. Washington, DC: US Food and Drug Administration; November 2007. Available at www.fda.gov/cder/foi/appletter/2007/018972s036LTR. pdf. Accessed December 28, 2008.
6. SDI, LLC: Vector One: National (VONA). Data extracted November 19, 2007.
7. SDI, LLC: Vector One: National (VONA). Data extracted November 20, 2007.
8. Pasternak RC, Smith SC, Bairey-Merz CN. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8.
9. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
10. Walters Kluwer Health, Inc. Facts & Comparisons 4.0. HMG-CoA reductase inhibitors monograph. Available at http://online.factsand comparisons.com. Accessed November 19, 2007, and July 7, 2008.
11. Welters Kluwer Health, Inc. Facts & Comparisons 4.0. Amiodarone hydrochloride oral monograph, http://online.factsandcomparisons.com. Accessed November 19, 2007.
12. Cordarone (amiodarone) package insert. Philadelphia, PA: Wyeth Laboratories; August 2004.
13. Zocor package insert. Whitehouse Station, NJ: Merck & Co, Inc.; August 2006.
14. Mevacor package insert. Whitehouse Station, NJ: Merck & Co, Inc.; May 2007.
15. National Cholesterol Education Program.Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. NIH Pub. No. 02-5215. Bethesda, MD: National Heart, Lung, and Blood Institute; 2002; 284 pages.
16. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008;31: 587-96.
17. White CM. HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary 2002;37:588-93.
18. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother 2005;39:1760-1.
19. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm 2003;60:698-700.
20. Ricaurte B, Guirguis A,Taylor HC et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006;40:753-7.
21. Schmidt GA, Hoehns JD, Purcell JL et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007;20:411-6.
22. Roten L, Schoenenberger RA, Krahenbuhl S et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38:978-81.
23. McElvie PA, Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature. J Clin Neuromusc Dis 2002;3:143-8.
24. Nägele H, Behrens S, Hashagen S et al. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. Drug Metabol Drug Interact 2007;22:195-200.